Researchers to watch rare muscle disease progression without treatment
NCT ID NCT06210672
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 26 times
Summary
This study aims to learn more about how gamma-sarcoglycanopathy (LGMDR5) changes over time. It will follow people aged 6 to 35 with a confirmed diagnosis for up to 24 months, measuring muscle function, breathing, and daily activity. No new treatments are tested; the goal is to gather information to help design future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GAMMA-SARCOGLYCANOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hedi Chaker Hospital Child Neurology Department
Sfax, Tunisia
-
Hopital Raymond Poincare
Garches, 92380, France
-
National Institute Mongi Ben Hmida of Neurology
Tunis, Tunisia
Conditions
Explore the condition pages connected to this study.